









Markets
/
Stocks
/
nasdaq-cai
/

Caris Life Sciences Inc

CAI

22.000USD

+0.750+3.53%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

6.21BMarket Cap

LossP/E TTM



Caris Life Sciences Inc

22.000

+0.750+3.53%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Caris Life Sciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Caris Life Sciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 58 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.89.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Caris Life Sciences Inc's Score

Industry at a Glance

Industry Ranking

58 / 205

Overall Ranking

162 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Caris Life Sciences Inc Highlights

StrengthsRisks

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Overvalued

The company’s latest PE is -4.36, at a high 3-year percentile range.

Held by George Soros

Star Investor George Soros holds 55.65K shares of this stock.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

37.889

Target Price

+78.30%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Caris Life Sciences Inc is 9.52, ranking 3 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

9.52

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.84

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.76

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Caris Life Sciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Caris Life Sciences Inc is 6.85, ranking 144 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -4.36, which is -3.41% below the recent high of -4.21 and -31.18% above the recent low of -5.72.

Score

Industry at a Glance

Previous score

6.85

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 58/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Caris Life Sciences Inc is 8.67, ranking 16 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 39.00, with a high of 45.00 and a low of 28.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

37.889

Target Price

+78.30%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Caris Life Sciences Inc

CAI

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Caris Life Sciences Inc is 6.62, ranking 114 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 26.94 and the support level at 19.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.45

Change

0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.860

Sell

RSI(14)

32.968

Neutral

STOCH(KDJ)(9,3,3)

9.787

Oversold

ATR(14)

1.392

High Vlolatility

CCI(14)

-113.732

Sell

Williams %R

85.813

Oversold

TRIX(12,20)

-0.674

Sell

StochRSI(14)

80.647

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

22.322

Sell

MA10

23.827

Sell

MA20

25.070

Sell

MA50

26.427

Sell

MA100

27.905

Sell

MA200

29.195

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Halbert (David D)

122.76M

-0.12%

Sixth Street Partners, LLC

24.39M

J.H. Whitney Capital Partners, LLC

20.26M

Castleman Peter M

10.37M

+32049.87%

Coatue Management, L.L.C.

Star Investors

10.14M

Fidelity Management & Research Company LLC

9.58M

+11.18%

T. Rowe Price Investment Management, Inc.

8.03M

+9.88%

Braidwell LP

7.32M

T. Rowe Price Associates, Inc.

Star Investors

6.92M

+2.29%

Silver Lake Partners

5.29M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Caris Life Sciences Inc is 5.34, ranking 83 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.